Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
DANUBE Trial - UROONCO Bladder Cancer
AstraZeneca Bladder Cancer Treatment Fails to Hit the Mark in Phase III Trial | BioSpace
DANUBE Trial - UROONCO Bladder Cancer
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Meeting Updates Refine Approaches Toward Urothelial Carcinoma
Overview of Microbicide Clinical Trials | Download Table
DANUBE Trial - UROONCO Bladder Cancer
The Korean Journal of Internal Medicine
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Cancers | Free Full-Text | Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma | HTML
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
Continued) Key clinical trials' efficacy data of ICIs in patients with... | Download Scientific Diagram
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis | BMJ Evidence-Based Medicine
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial - Clinical Genitourinary Cancer
Page 48 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
Is Danube Pharmaceuticals Inc. late reporting EU clinical trials?
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer
Management of metastatic bladder cancer - Cancer Treatment Reviews
